Sagit-Barfi et al. show that despite ineffective blockage of the PD-1/PD-L1 pathway with anti-PD-L1 alone, its combination with ibrutinib (molecule binding to Bruton’s tyrosine kinase) significantly enhanced the antitumor activity of T-cells in mice inoculated with breast and colon carcinoma, among others [20]. Here, CD274 is linked to colon carcinoma.